Replies to post #59125 on Biotech Values

[ThomasS]

SIMCOR: Isn't this really another attempt to counteract patient laziness, aka compliance? Isn't the 2 pill generic combo cheaper? If so, $500M speaks volumes about laziness...
(I also liked the blub, "simvastatin, a so-called statin...")